Navigation Links
Rutgers Business School's Pharma Industry Scholars Program offers students distinct advantages to help boost careers in healthcare industry
Date:3/6/2013

NEWARK, N.J., March 6, 2013 /PRNewswire-USNewswire/ -- Rutgers Business School offers MBA students who concentrate on pharmaceutical management a unique opportunity to make connections and gain the work experience to help advance their careers in the competitive healthcare industry.   

(Photo: http://photos.prnewswire.com/prnh/20130306/DC70929)  

A handful of incoming traditional full-time MBA students are chosen by Rutgers each year to participate in the prestigious Pharmaceutical Industry Scholars Program. The program provides chosen students -- prospective scholars must already be accepted to the MBA program and must have several years of work experience to be considered -- with money to cover the full cost of tuition, internships as well as access to executives and professionals in the pharmaceutical business.

Professor Mahmud Hassan , director of the Blanche and Irwin Lerner Center for the study of Pharmaceutical Management Issues, said scholars gain key advantages.  "The program's five sponsoring companies (Bayer, Bristol-Myers Squibb, Eisai, Johnson & Johnson and Novartis) know you by name," he said, "and they compete for you."

Hassan said students who become scholars also have opportunities to serve in leadership roles as members of the Rutgers Pharmaceutical Management Club and to supplement their resumes with new accomplishments and experiences.

To be considered for the Industry Scholars Program, candidates must have the following: a relatively high GMAT score; an undergraduate grade point average of 3.2 or higher; at least three years of business experience (not necessarily in the pharmaceutical business); and a demonstrated potential for leadership.

Candidates must also be goal-oriented and be able to demonstrate excellent communication skills and a record of superior achievement.

Those candidates who meet the criteria for the scholars program will be invited in for an interview with a selection committee made up of representatives from the five sponsoring companies. The selection committee makes the final decisions about scholarship winners. Students who are chosen to receive scholarship money may use it to cover in-state or out-of-state tuition plus college fees

Interviews with students who are selected as prospective scholars for the Class of 2015 will begin later this month and continue through May. 

Harleen Parmar , a Class of 2013 industry scholar, said the relationships scholars forge with representatives from the sponsoring pharmaceutical companies prove to be beneficial. "You do get a leg up on internships and jobs,'' she said, "but you still have to work hard."

Parmar, who spent six years working for pharmaceutical companies before she began her master's degree, landed an internship with Genentech, the South San Francisco-based biotechnology giant. When she completes her MBA later this semester, she hopes to return to the biotech industry.

"The main thing the scholars program gives you is the leverage to network with the pharmaceutical companies that sponsor the program," she said. "It really expands the breadth of your network."

Rutgers Business School's campuses in Newark and New Brunswick provide students are located in close proximity to one of the nation's leading pharmaceutical and biotechnology industry hubs. Each of the sponsoring companies – Bayer, Bristol-Myers Squibb, Eisai, Johnson & Johnson and Novartis – has a significant presence in the state.

The Rutgers MBA in Pharmaceutical Management is a reflection of the industry's importance in New Jersey and its quest for talent. Hassan said the Rutgers MBA concentration is differentiated by the depth of training it provides students and the expertise of its faculty. The MBA program at Rutgers is also bolstered by the presence of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management. The MBA program at Rutgers is also bolstered by the presence of the Blanche and Irwin Lerner Center for the Study of Pharmaceutical Management. The Center strives to position itself as a leading institution of innovative ideas and activities for the growth of the biopharmaceutical industry.

Laryssa Wozniak , another industry scholar, worked in the life sciences industry for five years before she started her MBA at Rutgers. "I knew I wanted to continue my career in the pharmaceutical industry," she said. "The program was perfect for me."

Wozniak said being in the scholar was like having a "back door pass" to the sponsoring pharmaceutical companies.

Like Hassan, Wozniak said the sponsoring companies are very aware of the scholars who they've chosen to invest in. "They know you have experience," she said. "They know you're choosing to stay in the industry. They look at that commitment."

Wozniak has worked at GlaxoSmithKline in marketing and marketing research since completing her Rutgers MBA. She is currently in the company's leadership development program and part of team focused on ground-breaking work in the area of patient engagement.

"It's an exciting place to be," she said.


'/>"/>
SOURCE Rutgers Business School
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. High Return-on-Investment Fueling Demand For Rutgers MBA Program
2. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
3. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
4. Nominations Open for San Francisco Business Times Health Care Heroes Awards
5. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
6. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
7. eCardios CEO to Speak During "Act at the Speed of Opportunity" Event Presented by Comcast Business Class and Inc.
8. myMatrixx Names Craig Rollins, Vice President of Ancillary and Business Development
9. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
10. Mylan Sponsors Drug Store News and Pharmacist Society to Provide a New Business Networking Platform for Pharmacy Schools and Students
11. Takeda to Acquire Multilab, Enhancing its Business Infrastructure in Brazil
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... 2017  NDS received FDA 510(k) clearance in May 2017 for ... stand specifically designed for endoscopy environments. An innovative secondary monitor solution, ... solution to support the improvement of patient outcomes, procedural efficiency, and ... ... ...
(Date:10/4/2017)... 2017  South Korean-based healthcare product Development Company I.M. ... on Kickstarter. The device will educate the user about ... better efficiency compared to the dated and pricey CPR ... efficacy of the compression for a more informed CPR ... to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... The American ... to become its next President and Chief Executive Officer, succeeding Dr. James C. Puffer ... Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of 2018. ...
(Date:10/13/2017)... Las Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... of 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum ... CBD dose required and providing a CBD form that can be easily incorporated into ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... a national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel ... also provides a forum to network with elder law attorneys nationwide,” said Somekh. ...
(Date:10/13/2017)... OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... or dementia. However, many long-term care insurance companies have a waiver for care if ... the 90-day elimination period, when the family pays for care, is often waived, so ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Ellevate Network, ... in business to advocate for action towards gender equality at their inaugural Summit in ... around the globe, and reached a social audience of over 3 million. To watch ...
Breaking Medicine News(10 mins):